|
|
|
| The influence of miR-144 on cell proliferation and cell cycle of papillary thyroid carcinoma cells |
| YU Mingjun, ZHAO Na, WANG Haiming |
| Department of Surgery, Hangzhou Third Hospital, Hangzhou 310009, China |
|
| Cite this article: |
|
YU Mingjun,ZHAO Na,WANG Haiming. The influence of miR-144 on cell proliferation and cell cycle of papillary thyroid carcinoma cells[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2020, 50(2): 120-124.
|
|
|
|
Abstract Objective: To evaluate the expression levels of miR-144 in papillary thyroid carcinoma (PTC) cell lines. To explore the influence of up-regulation/down-regulation of miR-144 on cell proliferation and cell cycle in PTC cells. Methods: The expression levels of miR-144 in PTC cells K1, TPC-1 and human thyroid cells Nthy-ori 3-1 were detected by qPCR. K1 cells were transiently transfected with miR-144 mimics, inhibitor, or the negative control (NC) by Lipo2000. After transfection, MTT assay, colony formation assay and flow cytometry were conducted to explore the impact of miR-144 on cell proliferation ability and cell cycle of K1 cells. Western blot was provided to detect the protein expression of Cyclin D1. Results: Compared with thyroid cells, the relative expression levels of miR-144 in PTC cells were significantly decreased (P<0.05). The expression of miR-144 in K1 cells was lowest. The overexpression of miR-144 suppressed K1 cell proliferation and colony formation, caused K1 cells arrested in G0/G1 phase, which relate to downregulation of Cyclin D1. Whereas, low expression of miR-144 promoted cell proliferation, colony formation and accelerate the process of cell cycle.Conclusion: miR-144 was down-regulated in PTC cells. miR-144 may act as a tumor suppressor in PTC by inhibiting cell proliferation and blocking cell cycle, suggesting its use as a potential therapeutic target.
|
|
|
| |
|
|
|
[1] LLOYD R V, BUEHLER D, KHANAFSHAR E. Papillary thyroid carcinoma variants[J]. Head Neck Pathol, 2011, 5(1): 51-56.
[2] SIEGEL R, NAISHADHAM D, JEMAL A. Cancer statistics, 2012[J]. CA Cancer J Clin, 2012, 62(1): 10-29.
[3] GRANT C S. Recurrence of papillary thyroid cancer after optimized surgery[J]. Gland Surg, 2015, 4(1): 52-62.
[4] LIU J, FENG L, ZHANG H, et al. Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation[J]. Cancer Biol Ther, 2018, 19(6): 484-496.
[5] LI J, SUN P, YUE Z, et al. miR-144-3p induces cell cycle arrest and apoptosis in pancreatic cancer cells by targeting proline-rich protein 11 expression via the mitogen-activated protein kinase signaling pathway[J]. DNA Cell Biol, 2017, 36(8): 619-626.
[6] MUSHTAQ F, ZHANG J, LI J. miR-144 suppresses cell proliferation and invasion in gastric cancer through downregulation of activating enhancer-binding protein 4[J]. Oncol Lett, 2019, 17(6): 5686-5692.
[7] JAHANBANI I, AL-ABDALLAH A, ALI R H, et al. Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features[J]. Thyroid, 2018, 28(3): 319-327.
[8] 巨涛. Survivin在甲状腺癌中的表达与细胞凋亡指数的关系[D]. 石家庄: 河北医科大学, 2014.
[9] 李安妮, 鲁明骞. microRNA在甲状腺癌中的研究进展[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(5): 397-400.
[10] GUAN H, LIANG W, XIE Z, et al. Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2[J]. Endocrine, 2015, 48(2): 566-574. |
|
|
|
